A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
Ovarian Neoplasms|Breast Neoplasms
DRUG: Niraparib
Number of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI), AEs, SAEs and AESI will be collected., Up to 5 years|Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance status, The performance status will be assessed using ECOG scale, where Grade 0 (fully active), Grade 1 (restricted in physically strenuous activity), Grade 2 (ambulatory and capable of all self-care), Grade 3 (capable of only limited self-care) and Grade 4 (completely disabled). Number of participants with clinically significant changes in ECOG performance status will be summarized., Up to 5 years|Number of participants with clinically significant changes in hematology and clinical chemistry parameters, Blood samples will be collected for the analysis of hematology and clinical chemistry parameters., Up to 5 years|Number of participants with clinically significant changes in vital signs, Number of participants with clinically significant changes in vital signs will be assessed., Up to 5 years|Number of participants with clinically significant changes in physical examination, Number of participants with clinically significant changes in physical examination will be assessed., Up to 5 years|Number of participants with use of concomitant medications, Number of participants using concomitant medications will be assessed., Up to 5 years
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.